Table 2.
Promising therapeutic trials of pembrolizumab
| Disease site | Disease site | Study acronyms | Design | Treatment line | Treatment |
|---|---|---|---|---|---|
| Lung | SCC | 604 | RC Phase III | 1st | CT + P or placebo |
| Stage IB-IIIA NSCLC | 091 (PEARLS) | RC Phase III | Adjuvant | CT followed by P or placebo | |
| Urothelial carcinomas | Bladder | PURE-01 | Phase II | Neoadjuvant | 3 cycles of P 200mg Q3W before surgery |
| Cisplatin eligible or ineligible advanced UC | 361 | R Phase III | 1st | P with or without CT vs CT alone | |
| Kidney cancer | 427 | Phase II | 1st | P | |
| Kidney cancer | 426 | RC Phase III | 1st | P + axitinib vs sunitinib | |
| breast | TNBC | 522 | Neoadjuvant | CT ± P followed by P or placebo as maintenance therapy | |
| CCR | MSI-high or MMR-deficient CCR | 164 | Phase II | ≥2 | P |
| MSI-high or MMR-deficient CCR | 177 | RC Phase III | 1st | P vs SOC chemotherapy | |
| Esophageal, GOJ and gastric carcinoma | Esophageal or GOJ carcinoma | 181 | R phase III | 2nd | P vs ICC |
| Advanced or metastatic esophageal carcinoma | 590 | RC phase III | 1st | Cisplatin +5FU + P or placebo | |
| PD-L1+, HER2- gastric or GOJ carcinoma | 062 | R phase III | 1st | P vs P+ CT (cisplatin +5FU) |
Abbreviations: P, pembrolizumab; R, randomised; RC, randomised controlled; CT, chemotherapy; ICC, investigator-choice chemotherapy; SOC, standard of care; PFS, progression-free survival; OS, overall survival; RFS, recurrence-free survival; Q2W, every two weeks; Q3W, every three weeks; UC, urothelial carcinoma; accRCC, advanced clear cell renal cell carcinoma; SCC, small cell carcinoma; NSCLC, non-small cell lung cancer; UC, urothelial carcinoma; TNBC, triple negative breast cancer; MSI, microsatellite instability; MMR, mismatch repair; CCR colorectal cancer; GOJ, gastro-oesophageal junction; HCC, hepatocellular carcinomas.